Advertisement
IDXX vs SYK
Which Stock Would AI Choose? IDEXX Laboratories, Inc. (IDXX) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- IDEXX Laboratories, Inc. (IDXX) focuses on veterinary diagnostics and software, while Stryker Corporation (SYK) specializes in medical devices and equipment, offering distinct exposure within the healthcare sector.
- In recent market activity, SYK reported Q2 2026 results with revenue of $6.59 billion and adjusted earnings per share (EPS) of $3.69, beating estimates, though shares declined approximately 6-7% post-earnings amid broader market reactions.
- IDXX is scheduled to release Q2 2026 results on August 4, 2026, following a Q1 beat; the stock has shown relatively stable performance in recent weeks compared to sector peers.
- SYK exhibits lower volatility with a beta around 0.77, while IDXX carries higher volatility with a beta of approximately 1.55, reflecting different risk profiles.
- Both companies demonstrate strong profitability metrics, with IDXX maintaining higher net margins and return on equity in recent periods.
- Market sentiment for SYK has been influenced by earnings delivery and recovery efforts from prior operational challenges, whereas IDXX sentiment centers on upcoming results and pet healthcare demand trends.
Introduction
This comparison examines IDEXX Laboratories, Inc. (IDXX) and Stryker Corporation (SYK), two healthcare-focused companies with complementary yet distinct business models. IDXX serves the animal health diagnostics market, while SYK operates in human medical technology. Traders and investors seeking to understand relative performance, sector positioning, and momentum within healthcare may find this analysis relevant for portfolio diversification or tactical allocation decisions in the current market environment.
IDXX Overview and Recent Performance
IDEXX Laboratories, Inc. (IDXX) develops and markets diagnostic products, software, and services primarily for companion animal veterinary practices. In recent weeks, the stock has traded with measured movements ahead of its scheduled Q2 2026 earnings release on August 4. Prior Q1 results showed an earnings beat, supporting steady sentiment. Broader market activity has been shaped by ongoing demand for pet healthcare solutions and macroeconomic factors affecting consumer spending. Performance has remained relatively consistent amid sector volatility, with investors monitoring indicators of growth sustainability.
SYK Overview and Recent Performance
Stryker Corporation (SYK) manufactures medical devices and equipment across orthopedics, medtech, and surgical technologies. Recent market activity featured the release of Q2 2026 results on July 30-31, delivering revenue of $6.59 billion and adjusted EPS of $3.69, which exceeded consensus estimates. Despite the solid operational results, shares declined notably following the report, influenced by factors including guidance interpretation and market rotation. The company continues efforts to recover from prior supply chain and cybersecurity issues while maintaining full-year outlook. Sentiment reflects resilience tempered by post-earnings price action in recent days.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a broader ecosystem of hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and risk parameters. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in the trending section. Performance statistics, win rates, and drawdown metrics differ widely across the bots, allowing users to review historical results and suitability. The section provides a dynamic view of automated trading options suited to current environments. Explore the full range at the Trending AI Robots page for detailed comparisons.
Head-to-Head Comparison
IDEXX Laboratories, Inc. (IDXX) and Stryker Corporation (SYK) differ in core business models, with IDXX concentrated in veterinary diagnostics and SYK diversified across human medical devices. Growth drivers for IDXX center on pet ownership trends and recurring diagnostic revenue, whereas SYK benefits from elective procedure volumes and innovation in orthopedics. Recent momentum shows SYK navigating post-earnings volatility, while IDXX maintains steadier positioning ahead of results. Risk factors include IDXX’s higher beta indicating greater market sensitivity and SYK’s exposure to healthcare policy and reimbursement changes. Sector exposure places both in healthcare but with limited direct overlap. Market sentiment currently balances SYK’s earnings delivery against IDXX’s upcoming catalysts, highlighting trade-offs in stability versus growth orientation.
Tickeron AI Verdict
Based on observable factors such as earnings consistency, volatility profiles, and relative positioning, Tickeron’s AI models would currently assign a modest probabilistic edge to IDEXX Laboratories, Inc. (IDXX) due to steadier recent price behavior and upcoming catalysts. However, Stryker Corporation (SYK) demonstrates resilience in operational metrics that could support outperformance if post-earnings sentiment stabilizes. The assessment remains conditional on evolving market data and trend persistence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDXX is a Hold and SYK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDXX’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- IDXX’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDXX’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 6 bullish TA indicator(s).
- IDXX’s TA Score: 5 bullish, 4 bearish.
- SYK’s TA Score: 6 bullish, 4 bearish.
Price Growth
IDXX (@Medical Specialties) experienced а +2.71% price change this week, while SYK (@Medical/Nursing Services) price change was -1.38% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
Reported Earning Dates
IDXX is expected to report earnings on Aug 04, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| IDXX | SYK | IDXX / SYK | |
| Capitalization | 44.1B | 125B | 35% |
| EBITDA | 1.56B | 6.44B | 24% |
| Gain YTD | -17.362 | -6.833 | 254% |
| P/E Ratio | 41.14 | 37.70 | 109% |
| Revenue | 4.45B | 25.3B | 18% |
| Total Cash | 201M | N/A | - |
| Total Debt | 1.11B | 14.7B | 8% |
IDXX | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 64 | |
SMR RATING 1..100 | 16 | 56 | |
PRICE GROWTH RATING 1..100 | 57 | 53 | |
P/E GROWTH RATING 1..100 | 69 | 82 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (10) in the Medical Specialties industry is significantly better than the same rating for IDXX (78). This means that SYK’s stock grew significantly faster than IDXX’s over the last 12 months.
SYK's Profit vs Risk Rating (64) in the Medical Specialties industry is somewhat better than the same rating for IDXX (100). This means that SYK’s stock grew somewhat faster than IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for SYK (56). This means that IDXX’s stock grew somewhat faster than SYK’s over the last 12 months.
SYK's Price Growth Rating (53) in the Medical Specialties industry is in the same range as IDXX (57). This means that SYK’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's P/E Growth Rating (69) in the Medical Specialties industry is in the same range as SYK (82). This means that IDXX’s stock grew similarly to SYK’s over the last 12 months.
| IDXX | SYK | |
|---|---|---|
| RSI ODDS (%) | N/A | 5 days ago 34% |
| Stochastic ODDS (%) | 4 days ago 69% | 4 days ago 61% |
| Momentum ODDS (%) | 4 days ago 67% | 4 days ago 51% |
| MACD ODDS (%) | 4 days ago 66% | 4 days ago 73% |
| TrendWeek ODDS (%) | 4 days ago 59% | 4 days ago 52% |
| TrendMonth ODDS (%) | 4 days ago 53% | 4 days ago 47% |
| Advances ODDS (%) | 6 days ago 58% | 6 days ago 56% |
| Declines ODDS (%) | 12 days ago 70% | 4 days ago 52% |
| BollingerBands ODDS (%) | 4 days ago 62% | 4 days ago 63% |
| Aroon ODDS (%) | 4 days ago 70% | 4 days ago 47% |
Advertisement
IDXX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | +0.05% | ||
| ALGN - IDXX | 50% Loosely correlated | -2.45% | ||
| SYK - IDXX | 48% Loosely correlated | -6.42% | ||
| BLCO - IDXX | 45% Loosely correlated | -0.47% | ||
| SNN - IDXX | 44% Loosely correlated | -2.38% | ||
| STE - IDXX | 40% Loosely correlated | -1.22% | ||
More | ||||
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.